Evidence map›Paper›PMID 42337706›Full record

ArticleBMC pulmonary medicine2026

Efficacy and optimal timing of sivelestat in critically ill patients with COVID-19: a multicenter retrospective cohort study.

Qi Zhang, Yijie Liu, Bowen Ran, Tianshu Zhai, Ying Cai, Chao Zhang, Jingcheng Hao, Longxian Jin, Zhenyuan Huang, Xiaojing Wu and 1 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qi ZhangBeijing University of Chinese Medicine, Beijing, 100105, China.
Yijie LiuNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China.
Bowen RanNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China.
Tianshu ZhaiNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China.
Ying CaiNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China.
Chao ZhangNational Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China.
Jingcheng HaoCapital Medical University, Beijing, 100069, China.
Longxian JinBeijing University of Chinese Medicine, Beijing, 100105, China.
Zhenyuan HuangBeijing University of Chinese Medicine, Beijing, 100105, China.
Xiaojing Wu *National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China. xpwxj@163.com.
Qingyuan Zhan *National Center for Respiratory Medicine; State Key Laboratory of Respiratory Health and Multimorbidity; National Clinical Research Center for Respiratory Diseases; Institute of Respiratory Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College; Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, 100029, P.R. China. drzhanqy@163.com.

Funding

National High Level Hospital Clinical Research Funding 2022-NHLHCRF-LX-01-01National High Level Hospital Clinical Research Funding & Elite Medical Professionals Project of China-Japan Friendship Hospital NO.ZRJY2023-GG20National Natural Science Foundation of China 82270108the Key Research and Development Program of Jiangxi province NO.20232BBG7002
6 · The paper itself

Abstract

backgroundThe cytokine storm is a pivotal factor in the progression of coronavirus disease 2019 (COVID-19) to severe disease. Sivelestat, recognized for its anti-inflammatory properties, holds promise as a therapeutic intervention for patients with severe COVID-19.

methodsWe conducted a multicenter, retrospective study involving patients admitted to the intensive care unit (ICU) with severe COVID-19 in China. A 1:2 propensity score matching (PSM) was employed to adjust for confounding factors and differences between the sivelestat and non-sivelestat groups.

resultsOur analysis involved 2030 patients with severe COVID-19. After applying a 1:2 PSM ratio, the sivelestat group consisted of 115 patients, while the non-sivelestat group comprised 211 patients. The findings indicated that sivelestat administration was associated with enhanced survival rates at 28 days for patients with severe COVID-19 (53.55% vs. 40.87%; P = 0.03). However, no significant differences were noted in the secondary outcomes, which included ventilator-free days within 28 days, gastrointestinal bleeding, septic shock, acute myocardial injury, venous thrombosis, acute liver injury, and acute kidney injury. Furthermore, this study revealed that early administration of sivelestat could reduce patient mortality.

conclusionsOur study suggests that sivelestat use may be associated with reduced 28-day mortality in ICU patients with severe COVID-19.

Indexed as

COVID-19 Drug TreatmentGlycineSulfonamidesAgedChinaCOVID-19Critical IllnessFemaleHumansIntensive Care UnitsMaleMiddle AgedPandemicsPropensity ScoreRetrospective StudiesSARS-CoV-2GlycineSerine Proteinase InhibitorssivelestatSulfonamidesICUPrognosisPropensity score matchingSevere COVID-19Sivelestat

Identifiers

PMID42337706
PMCPMC13548637

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.